Press Releases
-
Mar 6, 2019Aytu Assumes Milestone & Royalty-Based Licensing Agreement with SUDA Pharmaceuticals to Sublicense ZolpiMist Outside of the United States and Canada...Feb 7, 2019Company Posts Highest Ever Quarterly Revenue...Jan 31, 2019Live Conference Call and Webcast Scheduled for February 7, 2019, at 9:00 a.m. ET...Jan 15, 2019Tuzistra XR Enters the $3 Billion Cough and Cold Market, with 30-35 Million Prescriptions Written Annually...Jan 10, 2019Natesto Total Prescriptions Increased 27% and Refill Prescriptions Increased 52% Sequentially...Dec 6, 2018Nationwide availability for the first and only codeine-based, extended-release, oral-suspension cough/cold treatment in U.S. ...Dec 4, 2018Live Webcast at 9:00 am PT/12:00 pm ET Wednesday, December 5, 2018 ...Dec 3, 2018ENGLEWOOD, CO / ACCESSWIRE / December 3, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced two new appointments to the Company's board of directors. Ketan Mehta, Founder and Chief Executive Officer of Tris Pharma joined the board effective November 30, 2018. Ste...Nov 30, 2018Strategic Investment Positions Company with Approximately $19M in Cash ...Nov 27, 2018ENGLEWOOD, CO / ACCESSWIRE / November 27, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that Josh Disbrow, Chairman and Chief Executive Officer, and David Green, Chief Financial Officer, will present at the 11th Annual LD Micro Main Event investor conference...